Table 2.

Development of single nasal symptoms during the study. Improvement, deterioration, or unchanged status of single symptoms was assessed by patients and investigators.

	Patients' assessment		Total	Physicians' assessment		Total
	Group 1	Group 2		Group 1	Group 2
Rhinorrhoea
Reduced	11 (47.8%)	12 (48.0%)	23 (47.9%)	17 (68.0%)	22 (88.0%)	39 (78.0%)
Unchanged	9 (39.1%)	11 (44.0%)	20 (41.7%)	6 (24.0%)	3 (12.0%)	9 (18.0%)
Deteriorated	3 (13.0%)	2 (8.0%)	5 (10.4%)	2 (8.0%)	0 (0.0%)	2 (4.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher's exact test	P = 0.919			P = 0.221
Nasal itching
Reduced	7 (30.4%)	12 (48.0%)	19 (39.6%)	20 (80.0%)	22 (88.0%)	42 (84.0%)
Unchanged	13 (56.5%)	10 (40.0%)	23 (47.9%)	4 (16.0%)	2 (8.0%)	6 (12.0%)
Deteriorated	3 (13.0%)	3 (13.0%)	6 (12.5%)	1 (4.0%)	1 (4.0%)	2 (4.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher's exact test	P = 0.440			P = 0.830
Nasal obstruction
Reduced	11 (47.8%)	10 (40.0%)	21 (43.8%)	18 (72.0%)	22 (88.0%)	40 (80.0%)
Unchanged	7 (30.4%)	13 (52.0%)	23 (41.7%)	6 (24.0%)	2 (8.0%)	8 (16.0%)
Deteriorated	5 (21.7%)	2 (8.0%)	7 (14.6%)	1 (4.0%)	1 (4.0%)	2 (4.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher's exact test	P = 0.258			P = 0.347
Sneezing
Reduced	5 (21.7%)	12 (48.0%)	17 (35.4%)	18 (72.0%)	23 (92.0%)	41 (82.0%)
Unchanged	10 (43.5%)	11 (44.0%)	21 (43.8%)	3 (12.0%)	2 (8.0%)	5 (10.0%)
Deteriorated	8 (34.8%)	2 (8.0%)	10 (20.8%)	4 (16.0%)	0 (0.0%)	4 (8.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher's exact test	P = 0.039			P = 0.115